Navigation Links
L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
Date:1/14/2010

PARIS and NORTH BRUNSWICK, N.J., Jan. 14 /PRNewswire/ -- L'OREAL and Hurel Corporation ("Hurel") today jointly announced that they have achieved the initial milestone of a research and development collaboration to create a new and transformational in vitro test for potential allergic reactions to substances that could come into contact with the skin.  The new device, named "Allergy Test on a Chip™," is intended to comprise a technological substitute for the animal test known as the local lymph node assay ("LLNA").  LLNA is presently accepted by regulatory agencies worldwide as a standard means for evaluating potential allergenic responses to new ingredients of consumer and industrial products.

"We are extremely pleased to partner with Hurel in the development of Allergy Test on a Chip, which is totally in line with our 25-year commitment in non-animal toxicology," said Jacques Leclaire, Ph.D., Director of Life Sciences Research at L'OREAL.  "Hurel's microdevice represents cutting-edge research and development, directed towards creating a breakthrough technology complementing our efforts in building alternative, integrated testing strategies.  While the ultimate success of this advanced and complex research project is not a certainty, the critical goal it addresses makes it a most worthwhile endeavor for us as a company."

R&D activities of the collaboration are being performed by Hurel in the United States, with contributions by L'OREAL's scientific team.  Allergy Test on a Chip, a patented embodiment of Hurel's multi-tissue, microfluidic cell culture technology, will integrate a reconstructed human skin; a separate cell culture capable of simulating a human immune system response (i.e., an allergic reaction); and means of microfluidically-mediated signaling between the skin construct where the allergenic stimulus originates and the immune system construct where the response to that stimulus occurs.  

In its recently completed first year, the collaboration achieved its initial milestone of demonstrating the microfluidic signaling component of the device.  In vivo, in response to an allergen contacting the skin, certain cells migrate out of the skin and into a nearby lymph node, where they signal the immune system to launch an allergic reaction.  Achieving the initial milestone entailed simulating this process of migration in a prototype microfluidic device.

"We are gratified to have achieved the initial milestone of our collaboration, and thrilled to play a key role as L'OREAL spearheads new, non-animal testing methods in the cosmetics industry," commented Robert Freedman, Chief Executive Officer of Hurel Corporation.  "Allergy Test on a Chip, if globally adopted, may dramatically reduce the use of animal tests in safety evaluation; and in part for this reason it has considerable commercial potential as well.  L'OREAL deserves tremendous credit for making the investments that will help create the toxicology of the twenty-first century.  Hurel takes the greatest pride in collaborating with a company of L'OREAL's global stature."

About L'OREAL

L'OREAL is the world leader in the cosmetics industry, developing innovative products to meet the diverse needs of customers in 130 countries worldwide.  Nearly 3,000 people work in the Group's 18 research centers, located in France, Asia and America.  Their findings are responsible for the registration of hundreds of patents annually.  

About Hurel Corporation

Hurel Corporation is the world leader in developing microfluidic, multi-tissue cell cultures and assay platforms which provide in vitro alternatives to animal testing while offering improved human-relevance of toxicological and metabolic prediction to scientists in the pharmaceutical, biotech, cosmetics, consumer products and industrial products industries.  More information is available at http://www.hurelcorp.com/

SOURCE Hurel Corporation

RELATED LINKS
http://www.hurelcorp.com

'/>"/>

SOURCE Hurel Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stryker Corporation Announces Pricing of Senior Notes
2. CVS Caremark Corporation Increases Quarterly Dividend 15%
3. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
4. Somanetics Corporation to Release Fourth Quarter and Fiscal 2009 Financial Results and Host Conference Call January 21, 2010
5. Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices
6. Baxa Corporation to Sponsor Free Culture of Safety Webinar
7. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
8. Arrayit Corporation Announces Manufacturing Breakthrough
9. Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation
10. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
11. Neogen Corporation Announces 2nd Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
Breaking Medicine Technology:
(Date:4/22/2017)... New Freedom, PA (PRWEB) , ... April 22, ... ... of healthcare experience to his role as Vice President of Sales and Business ... direction of key GPO/IDN business partner engagements, business development, and strategic planning for ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to ... youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and ... involved in violence in the United States. The study, Trends in Fighting ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Dudnyk has announced ... emphasizes the agency’s conviction that the full potential of specialty and orphan brands can ... appreciated and aligned. , “The Unifying Effect is at the heart of a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):